(19)
(11) EP 3 406 608 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.01.2022 Bulletin 2022/03

(45) Mention of the grant of the patent:
15.09.2021 Bulletin 2021/37

(21) Application number: 18164959.1

(22) Date of filing: 05.01.2013
(51) International Patent Classification (IPC): 
C07D 401/14(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; C07D 401/14; A61P 35/02

(54)

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

THERAPEUTISCHE WIRKSTOFFVERBINDUNGEN UND VERFAHREN ZU IHRER VERWENDUNG

COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS PROCÉDÉS D'UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 06.01.2012 US 201261584214 P

(43) Date of publication of application:
28.11.2018 Bulletin 2018/48

(60) Divisional application:
21194846.8

(62) Application number of the earlier application in accordance with Art. 76 EPC:
13733752.3 / 2800743

(73) Proprietor: Les Laboratoires Servier
92284 Suresnes Cedex (FR)

(72) Inventors:
  • CIANCHETTA, Giovanni
    Boxford, MA 01921 (US)
  • DELABARRE, Byron
    Arlington, MA 02474 (US)
  • POPOVICI-MULLER, Janeta
    Windham, NH 03087 (US)
  • SALITURO, Francesco G.
    Malborough, MA 01752 (US)
  • SAUNDERS, Jeffrey O.
    Lincoln, MA 01773 (US)
  • TRAVINS, Jeremy M.
    Southborough, MA 01772 (US)
  • YAN, Shunqi
    Irvine, CA 92603 (US)
  • GUO, Tao
    Shanghai 200131 (CN)
  • ZHANG, Li
    Shanghai 200131 (CN)

(74) Representative: Jones Day 
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11
80538 München
80538 München (DE)


(56) References cited: : 
EP-A1- 0 466 647
 WO-A1-2010/144338
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).